Ramipril
Product Images NDC 21695-822

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Ramipril (NDC 21695-822). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rebel Distributors Corp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (00bdb48f 8b8f 4cc5 Bb63 77213f2279cb 01)

Structure (00bdb48f 8b8f 4cc5 Bb63 77213f2279cb 01)
Chemical structure of ramipril, showing its molecular components and bond configuration. The diagram includes aromatic rings, ester groups, amide linkages, and a carboxyl group, illustrating the detailed chemical composition of ramipril.*
FDA Label Image

Figure (00bdb48f 8b8f 4cc5 Bb63 77213f2279cb 02)

Figure (00bdb48f 8b8f 4cc5 Bb63 77213f2279cb 02)
A line graph comparing the proportion of patients over days of follow-up between Ramipril and placebo groups. The x-axis represents days of follow-up up to approximately 1600 days, and the y-axis shows the proportion of patients from 0.00 to 0.20. The Ramipril group is depicted with a solid line and the placebo group with a dashed line, showing a statistically significant difference (P=0.0001).*
FDA Label Image

Figure (00bdb48f 8b8f 4cc5 Bb63 77213f2279cb 03)

Figure (00bdb48f 8b8f 4cc5 Bb63 77213f2279cb 03)
A forest plot chart depicting the relative risk in the Ramipril group versus placebo for various patient subgroups. The chart lists subgroups by cardiovascular status, diabetes, age, sex, hypertension, history of coronary artery disease, prior myocardial infarction, cerebrovascular disease, peripheral vascular disease, and microalbuminuria. It shows the number of patients and incidence of composite outcomes in the placebo group, with relative risk and 95% confidence intervals illustrated by squares and horizontal lines.*
FDA Label Image

Ramipril 2.5mg (00bdb48f 8b8f 4cc5 Bb63 77213f2279cb 04)

Ramipril 2.5mg (00bdb48f 8b8f 4cc5 Bb63 77213f2279cb 04)
Label for Ramipril 2.5 mg capsules by Physician Partner, distributed by Rebel Distributors Corp. The label indicates 30 capsules per package, each containing 2.5 mg of Ramipril. It notes a hard gelatin capsule with a white body and orange opaque cap, featuring imprints "RP 2.5" and "logo." Storage instructions and caution to keep out of reach of children are included.*
FDA Label Image

Ramipril 5mg (00bdb48f 8b8f 4cc5 Bb63 77213f2279cb 05)

Ramipril 5mg (00bdb48f 8b8f 4cc5 Bb63 77213f2279cb 05)
Ramipril 5mg capsule label from Physician Partner, distributed by Rebel Distributors Corp. The label states packaging of 30 capsules, each containing 5mg of Ramipril. The capsules are described as hard gelatin with a white opaque body and red opaque cap, marked with "RP 5" and a black logo. The label includes storage instructions and a product ID PR082230CA.*
FDA Label Image

Ramipril 10mg (00bdb48f 8b8f 4cc5 Bb63 77213f2279cb 06)

Ramipril 10mg (00bdb48f 8b8f 4cc5 Bb63 77213f2279cb 06)
Ramipril 10 mg capsules packaging label from Physician Partner. The label indicates 60 capsules per bottle, each containing 10 mg of Ramipril. The capsules have a hard gelatin shell with a white body and blue cap. The label includes the product ID PR082360CA and lists manufacturing by Arrow Pharma (Malta) Ltd., Brindisi, Malta, with packaging by Physician Partner, Thousand Oaks, CA.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.